Two Cases of Acneiform Eruption Caused by Epidermal Growth Factor Receptor Inhibitors.
- Author:
Kyu Won CHOI
1
;
Chae Young LEE
;
Yeong Kyu LEE
;
Hong Seok KIM
;
Ki Ho KIM
;
Young Hun KIM
Author Information
1. Department of Dermatology, College of Medicine, Dong-A University, Busan, Korea. mucca@dau.ac.kr
- Publication Type:Case Report
- Keywords:
Cetuximab;
Epidermal growth factor receptor inhibitor;
Erlotinib
- MeSH:
Acneiform Eruptions;
Antibodies, Monoclonal, Humanized;
Epidermal Growth Factor;
Exanthema;
Hair;
Mucositis;
Paronychia;
Pruritus;
Quinazolines;
Receptor, Epidermal Growth Factor;
Skin;
Cetuximab;
Erlotinib Hydrochloride
- From:Korean Journal of Dermatology
2008;46(6):862-865
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatical dermatological side effects. The most commonly encountered adverse effect is a mild skin toxicity characterized by a sterile follicular and pustular rash that may be treated empirically and usually does not require treatment modification. Secondary adverse reactions seen with anti-EGFR therapy include xerosis, pruritus, paronychia, hair abnormality, and mucositis. According to the Korean literature, there are no reports of acneiform eruption induced by erlotinib (Tarceva(R)). We report a case of acneiform eruption induced by cetuximab (Erbitux(R)) and a case of acneiform eruption induced by erlotinib (Tarceva(R)).
